Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian, M.D., will speak at the Piper Sandler 34th Annual Healthcare Conference on November 30 at 4:00 p.m. ET, held at The Lotte New York Palace. Management will also engage in one-on-one meetings. A live webcast of the presentation will be accessible on the Syros website, with an archived replay available for 30 days. Syros focuses on innovative small molecules for gene expression control and is advancing a clinical-stage pipeline that includes therapies for various cancers.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Management will also be available for one-on-one meetings. Details are as follows:

Piper Sandler 34th Annual Healthcare Conference

Date: Wednesday, November 30
Time: 4:00 p.m. ET
Location: The Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005149/en/

Syros Contact

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

khunady@syros.com

Media Contact

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

bleigh@lifescicomms.com

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals present at the Piper Sandler conference?

Syros Pharmaceuticals will present at the Piper Sandler 34th Annual Healthcare Conference on November 30 at 4:00 p.m. ET.

Where is the Piper Sandler Healthcare Conference taking place?

The Piper Sandler Healthcare Conference will be held at The Lotte New York Palace, 455 Madison Avenue, New York, NY.

How can I access the Syros Pharmaceuticals presentation?

The presentation will be available via a live webcast on Syros Pharmaceuticals' website, with an archived replay for approximately 30 days.

What is the focus of Syros Pharmaceuticals' drug development?

Syros Pharmaceuticals focuses on developing medicines that control gene expression, targeting diseases that traditional genomics approaches have struggled to treat.

What are some of the key products in Syros Pharmaceuticals' pipeline?

Key products in Syros Pharmaceuticals' pipeline include tamibarotene for higher-risk myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for select solid tumors.